02:50:31 Europe / Stockholm

Prenumeration

2023-08-23 08:21:00

Redeye comments on Cantargia’s second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/